Falcone N
Departamento de Anestesiología, Reanimación y Terapéutica del Dolor, Hospital 12 de Octubre, Madrid, Spain.
Rev Esp Anestesiol Reanim. 2001 Dec;48(10):462-4.
Congenital heart disease can increase or decrease pulmonary blood flow, pulmonary vascular resistance (PVR) or pulmonary artery pressure (PAP). PAP is the product of PVR and pulmonary minute volume (Qp), such that pulmonary hypertension (PHT) may develop as a result of an increase in either PVR or Qp or both. Given that the pulmonary vascular bed is a low pressure system with high flow, any increase in resistance would generate PHT. The normal value of PVR is 2 Woods units (mm Hg/l/min). Increased PAP is due to hypoxic lesions of the endothelium, which release proteolytic enzymes that alter the balance of metabolites of arachidonic acid, regulators of pulmonary vasomotor tone. Hypoxia and acidosis cause intense pulmonary vasoconstriction (hypoxic vasoconstrictor reflex). An increase of PVR is due to a combination of vasoconstrictive processes and remodeling, with hypertrophy of the pulmonary artery. Structural lesions are related to hypertrophy of the endothelium, the transformation of fibroblasts to myocytes and the decrease of the alveolar/arteriolar ratio with the formation of new vessels.PHT may be primary or secondary to another disease. Primary PHT is a rare genetic disease. The most common secondary forms of PHT in pediatrics are due to persistence of neonatal anatomy (neonatal PHT), to heart diseases with left-right shunt (CIV, DAP, etc.), to diseases of the pulmonary parenchyma (interstitial viral infection, mucoviscidosis), and complications of heart surgery. All congenital heart diseases can lead to PHT if not treated promptly. Clinical signs of PHT are highly non-specific: dyspnea, fatigue, syncopes, exercise intolerance, precordialgia, cyanosis and edema. The best approaches to diagnosis and prognosis are echocardiography and cardiac catheterization with vasodilators. Anesthetics that do not alter PVR should be used in such patients, who are sensitive to changes in pulmonary ventilation, to changes in cardiac output and to anesthetics. The treatment of PHT during intra and postoperative pediatric surgery is based on the use of high inspirated oxygen concentration (100%), an adequate sedation and the use of vasodilators (prostaglandin I2, nitric oxide, sodium nitroprusiate and milrinone).
先天性心脏病可增加或减少肺血流量、肺血管阻力(PVR)或肺动脉压(PAP)。肺动脉压是肺血管阻力与肺每分钟血流量(Qp)的乘积,因此,肺动脉高压(PHT)可能是由于肺血管阻力增加、肺每分钟血流量增加或两者兼而有之所致。鉴于肺血管床是一个低压、高流量系统,任何阻力增加都会导致肺动脉高压。肺血管阻力的正常值为2伍兹单位(毫米汞柱/升/分钟)。肺动脉压升高是由于内皮细胞的缺氧性损伤,内皮细胞释放蛋白水解酶,改变了花生四烯酸代谢产物(肺血管舒缩张力调节剂)的平衡。缺氧和酸中毒会导致强烈的肺血管收缩(缺氧性血管收缩反射)。肺血管阻力增加是血管收缩过程和重塑共同作用的结果,伴有肺动脉肥大。结构病变与内皮细胞肥大、成纤维细胞向肌细胞的转化以及肺泡/小动脉比例降低并伴有新血管形成有关。肺动脉高压可能是原发性的,也可能继发于其他疾病。原发性肺动脉高压是一种罕见的遗传病。儿科最常见的继发性肺动脉高压形式是由于新生儿解剖结构持续存在(新生儿肺动脉高压)、左向右分流的心脏病(完全性肺静脉异位引流、大动脉转位等)、肺实质疾病(间质性病毒感染、黏液黏稠病)以及心脏手术并发症。所有先天性心脏病若不及时治疗都可导致肺动脉高压。肺动脉高压的临床症状极不具有特异性:呼吸困难、疲劳、晕厥、运动不耐受、心前区疼痛、发绀和水肿。诊断和预后的最佳方法是超声心动图和使用血管扩张剂的心脏导管检查。对于此类对肺通气变化、心输出量变化和麻醉药敏感的患者,应使用不改变肺血管阻力的麻醉药。小儿手术术中及术后肺动脉高压的治疗基于使用高吸入氧浓度(100%)、适当的镇静以及使用血管扩张剂(前列环素I2、一氧化氮、硝普钠和米力农)。